Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion
Zacks Investment Research | May 22, 2017 05:53AM ET
Novartis (NYSE:NVS) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive.
Upon approval, Zykadia will provide a new treatment option for previously untreated and newly diagnosed patients with ALK-positive advanced NSCLC.
Novartis’ has outperformed the Zacks classified industry year to date. The stock has rose 11.5% compared with the Large Cap Pharmaceuticals industry’s gain of 8.6%.
We note that Zykadia is currently approved in the European Union (EU) for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.
The European Commission will take the CHMP recommendation while reviewing the application but is not bound by it. A decision from the EC is expected within two months.
Earlier in the year, the FDA granted Zykadia Breakthrough Therapy designation for first-line treatment of patients with ALK-positive NSCLC with metastases to the brain. The application is under priority review in the U.S.
In Oct 2016, the FDA approved Merck & Co., Inc.’s (NYSE:MRK) Keytruda for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 as determined by an FDA-approved test. The approval was the first FDA approval of a checkpoint inhibitor for first-line treatment of lung cancer.
We remind investors that Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc’s (NYSE:GSK) certain oncology products and pipeline compounds in Mar 2015 after having divested its Animal Health Division to Eli Lilly and Company (NYSE:LLY) .
Going forward, we expect approval of new drugs and label expansion of existing ones to bode well for Novartis. Also, strong performance of growth products should be able to offset the impact of generic competition for Gleevec.
Zacks Rank
Novartis currently carries a Zacks Rank #3 (Hold). You can see .
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Get The News You Want
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.